The metabolic arms race has entered a new, more profitable phase. The FDA has approved 'Wegovy HD,' a triple-dosage variant of Novo Nordisk's blockbuster semaglutide injection, fast-tracked through the controversial National Priority Voucher program. This approval comes even as generic versions of the drug flood the Global South for as little as $15 a month following patent expirations in India and China. The result is a tiered biological reality: premium, high-potency molecules for the wealthy in the West, and generic scraps for the rest. The FDA’s 'voucher' scheme, which allows companies to skip the regulatory line, is increasingly viewed as a mechanism that prioritizes corporate profit over scientific rigor. While the agency touts 'therapeutic options,' it is actually facilitating a brand-protection strategy designed to keep Novo Nordisk's market share intact as cheaper alternatives emerge. We are witnessing the medicalization of the class divide, where health is not a right, but a premium subscription service with ever-increasing tiers of access.